About Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia
"L’IRCCS Ospedale San Raffaele è una struttura clinica-scientifica-universitaria di rilievo internazionale e di alta specializzazione per diverse importanti patologie, riconosciuta nel 1972 “Istituto di Ricovero e Cura a Carattere Scientifico” (IRCCS). La tematica della Medicina Molecolare è sempre stata l’elemento caratterizzante di questa Istituzione che ha scelto di focalizzare verso la comprensione dei processi molecolari e le applicazioni mediche delle scoperte della biologia molecolare con lo scopo di sviluppare terapie innovative per le patologie del sistema nervoso centrale e periferico, dell’apparato cardiovascolare e del metabolismo, per le patologie tumorali, le malattie infettive e immunomediate, le malattie genetiche e rare."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Clinical Trials at Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia
During the past decade, Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 3 clinical trials were completed, i.e. on
average, 13.6% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 2 clinical trials were completed. i.e. 15.4%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
2008-07-01
Completed
509
Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma
2005-12-01
2014-03-01
Unknown status
534
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
2010-01-01
2015-12-01
Completed
1,069
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
2009-09-01
2016-01-01
Completed
347
FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer
2001-11-01
2009-11-01
Completed
244
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
2012-11-27
2020-07-31
Completed
2,185
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
2012-01-01
2023-01-01
Active, not recruiting
159
A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)
2013-07-31
2019-05-28
Completed
159
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 11 trials, followed by "Fondazione Italiana Linfomi ONLUS" with 9 trials
sponsored, "Hoffmann-La Roche" with 6 trials sponsored, "Gruppo Oncologico del Nord-Ovest" with 2 trials sponsored and "Pfizer"
with 2 trials sponsored. Other sponsors include -5 different institutions and
companies that sponsored additional 5 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia"
#1 collaborator was "Janssen-Cilag S.p.A." with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator and "ERIC Group" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were
collaborators in the rest 3 trials.
Clinical Trials Conditions at Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia
According to Clinical.Site data, the most researched conditions in "Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia" are
"Chronic Lymphocytic Leukemia" (4 trials), "Breast Cancer" (2 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Chronic Myeloid Leukemia" (2 trials) and "AML, Adult" (1 trials). Many other conditions were trialed in "Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia" in a lesser frequency.
Clinical Trials Intervention Types at Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia
Most popular intervention types in "Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia" are "Drug" (26 trials), "Other" (4 trials), "Biological" (1 trials), "Genetic" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.
The name of intervention was led by "Venetoclax" (4 trials), "Rituximab" (3 trials), "Trastuzumab Emtansine" (3 trials), "Atezolizumab" (2 trials) and "PF-02341066" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia
The vast majority of trials in "Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia" are
30 trials for "All" genders.
Clinical Trials Status at Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia
Currently, there are NaN active trials in "Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia".
1 are not yet recruiting,
13 are recruiting,
7 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 8 completed trials in Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia, 1 "Phase 1"
clinical trials were conducted, 10 "Phase 2" clinical
trials and 12 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 1 trials that are defined as “Not Applicable".